ArticleInsights into imaging2025
Benefits and challenges of multi-delay arterial spin labeling in clinical practice: measuring perfusion and cerebrovascular reactivity in intracranial steno-occlusive disease.
Article in Insights into imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Recent advances in arterial spin labeling MRI for imaging brain tumors.Magma (New York, N.Y.) · 2026Review
- Perfusion as a biomarker of brain dysfunction in dementia (AD, DLB, FTD/PPA, PDD): comparison of CT, MRI (ASL/DSC/DCE), SPECT, and PET with interpretive pitfalls - a narrative review.Acta neurologica Belgica · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Magnetic resonance imaging (MRI) techniques have now widely replaced positron emission tomography (PET) as the modality of choice to assess cerebrovascular reactivity (CVR) and other hemodynamic parameters in intracranial steno-occlusive disease (ISOD), such as moyamoya vasculopathy (MMV). Therefore, radiologists should be aware of the choices in imaging techniques and potential pitfalls in the imaging interpretation. We developed a protocol based on multi-delay arterial spin labeling (ASL), with which, since its implementation in routine clinical practice in 2018, approximately 100 patients have been evaluated for CVR and other parameters. The protocol demonstrates clinical feasibility and utility, allowing detailed cerebral hemodynamic evaluations of individual patients that are useful for clinical decision-making. While multi-delay ASL offers benefits compared to single-delay ASL in patients with arterial transit delays, it is not completely insensitive to transit times, and further methodological improvements could mitigate this issue in the near future. Potential pitfalls in imaging acquisition and interpretation include artefacts due to motion, susceptibility, and misalignment in imaging registration, inadequate labeling, and the effects of anesthesia on CVR. This work serves as a practical guide for clinicians, radiologists, and MRI experts seeking to implement these advanced imaging methods in their institutions. CRITICAL RELEVANCE STATEMENT: Our MRI protocol, based on multi-delay ASL with a vascular challenge of acetazolamide, can be successfully used for hemodynamic assessments of patients with ISOD in clinical settings. KEY POINTS: We developed and implemented a protocol using acetazolamide-augmented multi-delay ASL for hemodynamic assessments in patients with steno-occlusive disease. Obtaining hemodynamic maps from ASL source data requires pre- and post-processing steps using customized toolboxes. CVR, if decreased, indicates hemodynamic compromise. Multi-delay ASL is not completely insensitive to delayed arterial transit, and technical improvements are needed to mitigate this.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.